Shalby Ltd Q2 FY26 – From Knee Replacements to Corporate Gymnastics: A 524x P/E Flex That Even Orthopedists Can’t Fix

1. At a Glance

Let’s start with the elephant in the operating room — a P/E ratio of 524. No, that’s not a typo, and yes, it’s higher than the number of bones your orthopedic surgeon can identify. Shalby Ltd (₹218/share, Market Cap ₹2,349 Cr) has positioned itself as India’s knee replacement king and a hospital chain that occasionally remembers profits exist. The company posted Q2 FY26 revenue of ₹285 Cr and PAT of ₹7.3 Cr, implying a QoQ profit growth of 147%, because when you go from a previous loss, even ₹1 looks like a miracle recovery.

Return on capital employed (ROCE) is a sleepy 6.1%, and ROE is a wheezing 0.6%, which means the hospital’s beds are working harder than its capital. Debt, meanwhile, has inflated to ₹535 Cr, proving that Shalby’s expansion drive has been as aggressive as its surgeons during a knee implant.

But here’s the fun part — Shalby is not just a hospital chain anymore. It’s also a medical device manufacturer, an asset-light franchise operator, and a world record holder in knee replacements. With over 1.5 lakh joint surgeries done, they’ve replaced more knees than most people have done squats.

The irony? Their patients are walking fine, but the stock price seems to be limping.

2. Introduction

Welcome to the land of scalpel capitalism, where hospitals are run like startups and every operation doubles as a press release. Shalby Ltd, founded by Dr. Vikram Shah, started as a one-hospital show in Ahmedabad and now moonwalks across 13 cities, 11 multispecialty hospitals, 5 orthopedic centers, and 83 clinics (60 in India + 23 abroad).

Over the years, the company became synonymous with Arthroplasty (that’s fancy medical Latin for “knee and hip replacement”) and claimed a 15% market share in India’s organized joint replacement market. It’s not an exaggeration to say they’ve put India on the world map of replacement surgeries — and probably in a few airport scanners too.

But as healthcare became “health business,” Shalby decided it’s not enough to just fix joints. So, they started fixing margins — through:

• Implant manufacturing in California (Shalby Advanced Technologies, Inc.),
• Franchise expansion under the SOCE (Shalby Orthopedic Centre of Excellence) model, and
• Aggressive M&A like the ₹102 Cr acquisition of Sanar International Hospital.

Yet, despite all the innovation and robotic surgeries (yes, they did the world’s first fully autonomous robotic joint replacement in 2025), the company’s financials make one wonder: did they accidentally replace their profit margin with a prosthetic one?

3. Business Model – WTF Do They Even Do?

Alright, here’s the anatomy of Shalby’s business model dissected without anesthesia:

1. Healthcare Services (90% of H1 FY25 revenue):
This is the bread and butter — or rather, the bone and marrow — of the company. Shalby runs multispecialty tertiary care hospitals providing over 30+ specializations, from orthopedics and cardiology to oncology and neurology.
In H1 FY25, they treated:

• 46,699 in-patients,
• 2,78,137 out-patients,
• 16,529 surgeries,
  with an ARPOB (Average Revenue Per Occupied Bed) of ₹41,072.

Occupancy stands at 48%, which sounds bad till you realize most Indian hospitals average around 55%. The company’s challenge? Filling beds without giving discounts that make it look like an Amazon sale.

2. Implants Business (10% of H1 FY25 revenue):
Through Shalby Advanced Technologies Inc. (SAT) in California, they manufacture knee and hip implants, exporting to the USA, Japan, and Indonesia. Production capacity has ramped up to 4,600 units/month, and the goal is a $100 million business.

Revenue Mix Q2 FY25:

• India: 70%
• USA: 30%
• Knee implants: 84%
• Hip implants: 16%

Basically, Shalby now makes the parts it installs — the full orthopedic circle of life.

3. Franchise & Asset-Light Model (SOCE):
They operate through FOSO (Franchise Owned, Shalby Operated) and FOSM (Franchise Owned, Shalby Managed). Four franchises are operational, and 40 more are planned. Think of it like McDonald’s, except instead of burgers, you get titanium knees.

4. International Clinics:
With 23 international clinics, Shalby has become an NRI-friendly healthcare brand. You can now get your knee fixed in Ahmedabad and your follow-up done in Dubai. Globalization, but with anesthesia.

4. Financials Overview

Quarterly Performance Comparison (₹ Cr):

Annualized EPS = ₹0.78 × 4 = ₹3.12 → P/E = 218 / 3.12 = ~69.9,
but reported P/E is 524 — because apparently, math goes under anesthesia too.

Commentary:
The operating margin (OPM) of 14.6% looks okay until you realize hospital chains like Max or Apollo hover above 20%. Still, a 147% profit growth QoQ sounds heroic after the company’s FY25 loss-making quarters. One must admire the resilience — or perhaps the accounting dexterity.

5. Valuation Discussion – Fair Value Range Only

Let’s attempt financial surgery using three methods.

a) P/E Method:
Peer median P/E ≈ 55x (from Max, Apollo, Fortis,